Zhuhai Rundu’s Higenamine Receives NMPA Approval as China’s First Category 1 Cardiac Stress Test Agent
China’s National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1...
Drug
Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China’s...
Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
Youcare Pharmaceutical Group (SHA: 688658) announced that its YKYY018 aerosolized inhalation formulation has received approval...
Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen
Merck & Co., Inc. (MSD, NYSE: MRK) announced that the European Commission has granted marketing...
Merck Launches Pivotal Phase 2b/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment
Merck & Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b/3...
Bio-Thera Solutions Gains NMPA Clearance for Phase I/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors
Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China’s National Medical Products Administration (NMPA) has approved...
AstraZeneca’s Imfinzi-Imjudo Combo with Lenvatinib and TACE Shows Significant PFS Benefit in Early-Stage Liver Cancer, EMERALD-3 Trial Reveals
AstraZeneca plc (NYSE: AZN) announced positive top-line results from the EMERALD-3 Phase III clinical trial,...
RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors
RemeGen Ltd (HKG: 9995) announced it has received approval from China’s National Medical Products Administration...
Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received approval...
NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal
China’s National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide...
Sichuan Biokin Receives NMPA Approval for Phase II/III Trials of First-in-Class Bispecific ADC Iza-bren in Prostate and Ovarian Cancers
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced it has received approval from China’s National...
Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer
Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Amgen Inc. (NASDAQ: AMGN) announced a strategic collaboration...
Eli Lilly Secures FDA Approval for Foundayo (Orforglipron) in Obesity Treatment, Shipments Begin April 6
Eli Lilly and Company (NYSE: LLY) announced it has received marketing approval from the US...
Eisai Expands Dayvigo Access in China with 14-Tablet Specification Across E-Commerce and Digital Health Platforms
Eisai Co., Ltd. (TYO: 4523) announced the commercial launch of a 14-tablet specification of its...
Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received clearance...
Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
Rui Therapeutics, a China-based cell therapy developer, announced it has received approval from the National...
Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received approval...
Alphamab Oncology’s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study
Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in...
Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease
Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has granted conditional marketing authorization for...
Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy
Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved...